Skip to main content

Table 9 Sample classification after LDA to discriminate between CSF samples from patients with Relapse–remitting multiple sclerosis (RRMS) vs. other diseases (inflammatory and non-inflammatory) of the CNS (INF and N-INF) based on the identified protein spots

From: Posttranslational modifications of proteins are key features in the identification of CSF biomarkers of multiple sclerosis

 

Classification resultsb,c

Disease

Predicted Group Membership

Total

RRMS

INF and N-INF

Original

 Count

RRMS

57

12

69

INF and N-INF

11

58

69

 %

RRMS

82.6

17.4

100

INF

15.9

84.1

100

Cross-validateda

 Count

RRMS

56

13

69

INF and N-INF

11

58

69

 %

RRMS

81.2

18.8

100

INF & N-INF

15.9

84.1

100

  1. aCross validation is done only for those cases in the analysis. In cross validation, each sample is classified by the functions derived from all samples other than the one under analysis
  2. b83.3% of original grouped cases correctly classified
  3. c82.6% of cross-validated grouped cases correctly classified
Back to article page

Journal of Neuroinflammation

ISSN: 1742-2094